Bart Spiesschaert
Bart Spiesschaert has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Guido Wollmann
Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria
1 shared publication - John Edward Park
Boehringer Ingelheim Pharma GmbH & Co KG, Biberach 88937, Germany
1 shared publication - Katharina Angerer
Christian Doppler Laboratory for Viral Immunotherapy of Cancer, Medical University Innsbruck, 6020 Innsbruck, Austria
1 shared publication - Saurabh Gautam
Boehringer Ingelheim International GmbH
1 shared publication
Latest Publications
- 11 August 2023
- Published by Springer Nature
- p. 429-442
Oncolytic Viruses and Viral Gene Therapy Vectors: Principles of Safety
- 11 August 2023
- Published by Springer Nature
- p. 429-442
Oncolytic Viruses and Viral Gene Therapy Vectors: Principles of Safety
- Open Access
Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits
The focus of treating cancer with oncolytic viruses (OVs) has increasingly shifted towards achieving efficacy through the induction and augmentation of an antitumor immune response. However, innate antiviral responses can limit the activity of many OVs within the tumor and several immunosuppressive factors can hamper any subsequent antitumor immune responses. In recent decades, numerous small molecule compounds that either inhibit the immunosuppressive features of tumor cells or antagonize antiviral immunity have been developed and tested for. Here we comprehensively review small molecule compounds that can achieve therapeutic synergy with OVs. We also elaborate on the mechanisms by which these treatments elicit anti-tumor effects as monotherapies and how these complement OV treatment.
Open AccessCombining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits
The focus of treating cancer with oncolytic viruses (OVs) has increasingly shifted towards achieving efficacy through the induction and augmentation of an antitumor immune response. However, innate antiviral responses can limit the activity of many OVs within the tumor and several immunosuppressive factors can hamper any subsequent antitumor immune responses. In recent decades, numerous small molecule compounds that either inhibit the immunosuppressive features of tumor cells or antagonize antiviral immunity have been developed and tested for. Here we comprehensively review small molecule compounds that can achieve therapeutic synergy with OVs. We also elaborate on the mechanisms by which these treatments elicit anti-tumor effects as monotherapies and how these complement OV treatment.